BioNTech Shares Fall After Ending Phase 2 Colorectal Cancer Trial

MT newswire2026/08/28 13:49

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

09:49 AM EDT, 08/28/2026 (MT Newswires) -- BioNTech (BNTX) shares fell 9% in early Friday trading after the company said it has decided to terminate a phase 2 trial evaluating autogene cevumeran as an adjuvant monotherapy in patients with high-risk stage II or stage III colorectal cancer. The trial's independent safety board recommended discontinuing treatment and ending the trial, saying further continuation was unlikely to change the efficacy outcome, according to the company. A separate phase 2 trial evaluating autogene cevumeran in combination with checkpoint inhibition and chemotherapy for adjuvant pancreatic ductal adenocarcinoma is not affected and will continue as planned, the company said. Price: 101.50, Change: -9.90, Percent Change: -8.89

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to reports, the trading firm JonesTrading is marketing up to $500 million worth of stock shares on behalf of some investors, at a 3% to 5% premium over the IPO issue price. This indicates that investors are already transferring their anticipated IPO allotted shares before the IPO is officially issued.

华尔街见闻•2026/11/10 23:03